| Description | The antibody CV07-250 is a human mAb specific for SARS-CoV-2 Spike S1 protein. The strongest neutralizing mAb reduced ACE2 binding to the RBD to 58.3%. The binding mode of antibody to the RBD is unusual in that it is dominated by the light chain. It uses CDR H1, H3, L1, and L3 and framework region 3 (LFR3) for RBD interaction. It (IC50 = 3.5 ng/mL) had 33 SHMs (17/16 on the heavy and light chain, respectively) and strongly reduced ACE2 binding and showed no binding to murine tissue. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | Receptor-binding domain (RBD) |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA, Neut |
| Application Notes | The IC₅₀ value of the mAb is 3.5 ng/mL. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Western Blot Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
